Related Experiment Video

Updated: May 21, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity

A D Whale1, A Dart, M Holt

  • 1Randall Division of Cell and Molecular Biophysics, King's College London, London, UK.

Oncogene
|June 13, 2012
PubMed

Insights

p21-activated kinase 4 (PAK4) activity is essential for cancer cell migration, as it phosphorylates LIM kinase 1 (LIMK1). A specific mutation (E329K) enhances PAK4

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Medicine

Background:

  • Hepatocyte growth factor (HGF) and its receptor (c-Met) signaling pathways drive cancer cell invasion.
  • p21-activated kinase 4 (PAK4) is recruited and activated by c-Met, phosphorylating LIM kinase 1 (LIMK1) and promoting cell motility.
  • The role of PAK4 kinase activity in HGF-driven cancer cell migration remains unclear.

Purpose of the Study:

  • To investigate the requirement of PAK4 kinase activity in HGF-induced carcinoma cell motility.
  • To elucidate the functional consequences of PAK4 mutations, including the E329K variant, on cell migration and therapeutic targeting.

Main Methods:

  • Utilized a combination of PAK4 overexpression and RNA interference (RNAi) rescue experiments.
  • Employed a panel of PAK4 truncations and kinase-inactive mutants to assess functional requirements.
  • Analyzed the impact of PAK4 mutations on cell migration speed and LIMK1 phosphorylation.

Main Results:

  • PAK4 kinase activity, along with associated LIMK1 activity, is crucial for carcinoma cell motility.
  • Neither the isolated kinase domain nor a Cdc42-binding deficient PAK4 mutant could fully restore motility in PAK4-deficient cells.
  • Overexpression of the PAK4 E329K mutant enhanced HGF-driven cell motility and suggested increased kinase activity and resistance to ATP inhibitors.

Conclusions:

  • PAK4 kinase activity is essential for HGF-mediated cancer cell migration, establishing PAK4 as a potential anti-metastatic therapeutic target.
  • The somatic mutation E329K in PAK4 enhances motility and may confer resistance to inhibitors, impacting future therapeutic strategies.
  • Further exploration of PAK4 as a clinical target is warranted, considering the implications of activating mutations.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...